Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles vaccine + MVA-mBN85B
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**measles vaccine + MVA-mBN85B** is a prophylactic vaccine combination designed to induce immunity against measles virus infection. It pairs a standard live attenuated measles vaccine with MVA-mBN85B, a highly attenuated recombinant Modified Vaccinia Ankara (MVA-BN) viral vector expressing measles virus hemagglutinin (H), fusion (F), and nucleoprotein (N) antigens. Developed by Bavarian Nordic, MVA-mBN85B leverages the non-replicating nature of MVA-BN in human cells to safely elicit robust humoral and cellular immune responses, including neutralizing antibodies and T-cell responses, even in the presence of maternal antibodies or pre-existing immunity. It demonstrates superior immunogenicity compared to conventional measles vaccines in preclinical models and has been evaluated for safety and efficacy in pediatric populations aged 6 months to 6 years.[1][3][5]
- Other names
- Measles vaccine (Bavarian Nordic)
02
Targets
N (Nucleocapsid protein)MV-H (Measles virus hemagglutinin protein)F (Coagulation factors)
Beyond the preview
Go deeper on measles vaccine + MVA-mBN85B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles vaccine + MVA-mBN85B.